[1] LATGÉ J P, CHAMILOS G. Aspergillus fumigatus and aspergillosis in 2019[J]. Clin Microbiol Rev, 2019, 33(1)e00140-18. [2] BRAKHAGE A A. Systemic fungal infections caused by Aspergillus species:epidemiology, infection process and virulence determinants[J]. Curr Drug Targets,2005, 6(8):875-886. [3] WALSH T J, ANAISSIE E J, DENNING D W, et al. Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3):327-360. [4] ARENDRUP M C, MAVRIDOU E, MORTENSEN K L, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence[J]. PloS One, 2010, 5(4):e10080. [5] DENNING D W, RADFORD S A, OAKLEY K L, et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection[J]. J Antimicrob Chemother, 1997, 40(3):401-414. [6] LIU M, ZENG R, ZHANG L, et al. Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China[J]. Antimicrob Agents Chemother, 2015, 59(7):4321-4325. [7] BUEID A, HOWARD S J, MOORE C B, et al. Azole antifungal resistance in Aspergillus fumigatus:2008 and 2009[J]. J Antimicrob Chemother, 2010, 65(10):2116-2118. [8] 李冉, 张大志. 氮唑类抗真菌药物靶酶CYP51的研究进展[J]. 药学实践杂志, 2016, 34(2):106-109. [9] FRACZEK M G, BROMLEY M, BOWYER P. An improved model of the Aspergillus fumigatus CYP51A protein[J].Antimicrob Agents Chemother, 2011, 55(5):2483-2486. [10] LOCKHART S R, FRADE J P, ETIENNE K A, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51Agene[J]. Antimicrob Agents Chemother, 2011, 55(9):4465-4468. [11] TESTING S.EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds[J]. Clin Microbiol Infect, 2008, 14(10):982-984. [12] MELLADO E, DIAZ-GUERRA T M, CUENCA-ESTRELLA M, et al. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B)in Aspergillus fumigatus and other Aspergillus species[J]. J Clin Microbiol, 2001, 39(7):2431-2438. [13] BADER O, WEIG M, REICHARD U, et al. cyp51A-Based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany[J]. Antimicrob Agents Chemother, 2013, 57(8):3513-3517. [14] PERLIN D S, WIEDERHOLD N P. Culture-independent molecular methods for detection of antifungal resistance mechanisms and fungal identification[J]. J Infect Dis, 2017, 216(Suppl 3):S458-S465. [15] SPIESS B, SEIFARTH W, MERKER N, et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatuscyp51Agene in primary clinical samples from neutropenic patients[J]. Antimicrob Agents Chemother, 2012, 56(7):3905-3910. [16] PÉREZ-CANTERO A, LÓPEZ-FERNÁNDEZ L, GUARRO J, et al. Azole resistance mechanisms in Aspergillus:update and recent advances[J]. Int J Antimicrob Agents, 2020, 55(1):105807. |